Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Akero Histology Data Could Be Best In Class For NASH

Jul 01 2020

• By Joseph Haas

Female person holding red human liver model at white body — Akero's FGF21 analog may offer antifibrotic and NASH-resolution benefits

Related Content

Intercept’s CRL Just Continues Upheaval In NASH

Jun 29 2020

RESOLVE-IT Failure Dashes Genfit's NASH Hopes

May 12 2020

89Bio’s NASH Hopes Hang On Demonstrating Best-In-Class FGF21 Profile

Feb 11 2020

NGM’s Pan-FGF Receptor Approach In NASH Shows Benefits And Drawbacks

Feb 24 2020

Akero Heads To Top Of FGF21 Class In NASH; Genfit Says Pandemic Won’t Delay Phase III

Mar 31 2020

Intercept’s NASH NDA Positions OCA For May 2020 Approval, Then Launch

Sep 30 2019

With Phase III NASH Endpoints In Place, Intercept May Reach Market By 2018

May 19 2015

Related Companies

Akero Therapeutics, Inc.

89bio, Inc.

Bristol Myers Squibb Company

Merck & Co., Inc.

Roche Holding AG

Novo Nordisk A/S

NGM Biopharmaceuticals, Inc.

Genfit SA

Intercept Pharmaceuticals, Inc.

Additional Topics

Clinical Trials Research & Development Liver & Hepatic BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window